Compare Incyte Corporation (INCY) vs Mondaycom Ltd (MNDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Mondaycom Ltd — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while Mondaycom Ltd trades at $75.09 (market cap $3.24B). The key difference: Incyte Corporation is far larger — about 7.1× Mondaycom Ltd's market cap, and Incyte Corporation is trading nearer its 52-week high, Mondaycom Ltd nearer its low. Which is the better fit depends on your goals.
| INCY | MNDY | |
|---|---|---|
Market Cap | $23.11B | $3.24B |
Sector | Health | Technology |
52-Week High | $118.52 | $292.24 |
52-Week Low | $67.38 | $58.81 |
Enterprise Value | $19.13B | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Monday.com trades at $76.75, down 2.47% on the day, with technical indicators showing neutral signals. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.15 beating expectations of $0.96. Revenue grew to $1.23 billion in 2025 with a healthy 89.05% gross margin. Analyst sentiment remains bullish with 76% buy ratings and a $115.50 consensus price target representing 50% upside potential. Recent news highlights institutional selling but positive coverage of the company's AI-driven work management platform.
The stock presents a compelling opportunity given its strong earnings track record, high analyst conviction, and attractive valuation discount to price targets. Key risks include competitive pressures in the SaaS space and the stock's high valuation multiples. The company's transition to a 'seats + credits' pricing model and AI integration provide growth catalysts, though investors should monitor execution against 2026 guidance and cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →
